Other Routine +

BriaCell Phase 3 Bria-IMT(TM) Study Enrollment Surpasses 230 Patients

BriaCell Therapeutics Advances Phase 3 Enrollment Amidst Stock Consolidation Near Historic Lows

By The Northwire Desk — AI Analysis May 12, 2026 · 07:30 BCT · 5.66 BRIACELL THERAPEUTICS CORP. J

Executive Summary

Enrollment Progress: The most recent release (May 12, 2026) confirms enrollment in the pivotal Phase 3 Bria-ABC study has surpassed 230 patients, up from over 160 reported in December 2025.
Data Readout Timeline: Interim topline data is expected in 2026, triggered by 144 patient events (deaths) for the overall survival primary endpoint.
Regulatory Status: The Bria-IMT combination regimen retains FDA Fast Track designation.
External Recognition: The trial was featured in Nature Medicine’s article regarding trials shaping medicine in 2026, a point reiterated from previous coverage.
Clinical Sites: Recent additions include NYU Langone Health (May 7) and other major centers previously announced, supporting the enrollment momentum.
Pipeline Expansion: FDA clearance was received for Bria-BRES+ IND application (May 6), enabling Phase 1/2a studies in metastatic breast cancer alongside the pivotal Phase 3 program.

Material Impact

Enrollment Milestone: The increase from 160 to 230 enrolled patients is consistent with the previously announced timeline for H1 2026 data readout. It confirms operational execution but does not introduce new efficacy or safety surprises that would fundamentally alter valuation expectations.
Market Expectations: Given the stock's significant decline from $49.50 to ~$5.66 over the past year, the market has likely priced in the risk of trial failure and dilution. Enrollment progress is a baseline requirement for Phase 3 trials rather than a catalyst for re-rating unless it signals an accelerated readout date.
Financing Context: The company closed a $30 million public offering in January 2026 at ~$15 per unit, which subsequently saw the stock price drop to ~$6 immediately following pricing and closing. This indicates significant dilution pressure or market skepticism regarding capital efficiency.
Catalyst Timing: The primary catalyst remains the interim data readout (triggered by 144 deaths). Enrollment progress supports this timeline but does not guarantee positive results.
Conclusion on Materiality: The news is positive for operational continuity but lacks the "unexpected" element required for a Material Positive rating. It validates the path to the next binary event without changing the risk/reward profile significantly.

BCT · Price

Company Overview

Company: BriaCell Therapeutics Corp. focuses on cancer immunotherapy using whole-cell based vaccines.
Flagship Project: Bria-IMT (SV-BR-1-GM) in combination with an immune checkpoint inhibitor for advanced/metastatic breast cancer.
Development Stage: Pivotal Phase 3 trial (Bria-ABC).
Mechanism: Allogenic whole-cell-based cancer vaccine designed to activate innate and adaptive immunity.
Secondary Platform: Bria-BRES+ (next-generation personalized off-the-shelf immunotherapy) recently received IND clearance for Phase 1/2a.

More from BRIACELL THERAPEUTICS CORP. J